Sesen Bio announced that its stockholders have voted to approve all proposals, including the pending merger with Carisma Therapeutics, at the Company’s Special Meeting of Stockholders.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SESN:
- Sesen Bio reports Q4 EPS (4c), consensus (11c)
- Sesen Bio announces Glass Lewis recommendation to vote for merger with Carisma
- Sesen Bio boosts special cash dividend to 36c per share, Torok to join board
- Sesen Bio gets Nasdaq delisting notice, company sees Carisma deal as viable path
- Sesen Bio: Pending Carisma merger in best interests of stockholders
